Market capitalization | $3.42m |
Enterprise Value | $-1.33m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.16 |
P/B ratio (TTM) P/B ratio | 0.54 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-9.54m |
Free Cash Flow (TTM) Free Cash Flow | $-8.36m |
Cash position | $4.86m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Artelo Biosciences Inc forecast:
4 Analysts have issued a Artelo Biosciences Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -9.54 -9.54 |
6%
6%
|
EBIT (Operating Income) EBIT | -9.54 -9.54 |
6%
6%
|
Net Profit | -9.12 -9.12 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company was founded by James Manley on May 2, 2011 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Gregory Gorgas |
Employees | 6 |
Founded | 2011 |
Website | www.artelobio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.